Other languages CanSino Biologics Inc. Shanghai S.E.

Equities

688185

CNE100004BM0

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-06-11 EDT			5-day change	1st Jan Change
48.29 ^CNY	-0.45%		-1.00%	-35.20%

06-10	Indonesia ramps up fight against tuberculosis amid concerns on economic impact	RE
05-31	CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Indonesia ramps up fight against tuberculosis amid concerns on economic impact	06-10
CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee	05-31
Cansino Biologics Invests 160 Million Yuan in China Bohai Bank’s Structured Deposits	05-21
CanSino Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29
CanSino Biologics Inc. Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China	04-22
Cansino Biologics Begins Phase III Clinical Trials for Tetanus Drug	03-20
Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	03-20
Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine	02-28
CanSino Biologics' Loss Widens in 2023, Misses EPS, Revenue Estimates; Shares Rise 4%	02-26
Cansino Biologics Inc. Announces Board and Committee Elections	02-23
CanSino Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23
CanSino Biologics Deconsolidates CanSino SPH	02-02
CanSino Biologics' Loss to Widen in 2023; Shares Drop 5%	01-31
CanSino Biologics' 13-Valent Pneumococcal Vaccine Trial Shows Positive Results	01-31
Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023	01-30
CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine	01-30
Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine	01-15
AstraZeneca comprará la china Gracell Biotechnologies en una operación de 1.200 millones de dólares	12-26
CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	12-20
Scientists see risk of lost opportunity for long COVID research in China	12-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

INTERVIEW - Xuefeng Yu, CEO of CanSino Biologics: Behind the scenes of the agreement with AstraZeneca

August 31, 2023 at 06:08 am